Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7ZXU

SARS-CoV-2 Omicron BA.4/5 RBD in complex with Beta-27 Fab and C1 nanobody

Summary for 7ZXU
Entry DOI10.2210/pdb7zxu/pdb
DescriptorSpike protein S1, Nanobody C1, Beta-27 heavy chain, ... (9 entities in total)
Functional Keywordssars-cov-2, omicron ba.4, ba.5, rbd, antibody, fab, beta-27, viral protein/immune system, viral protein
Biological sourceSevere acute respiratory syndrome coronavirus 2
More
Total number of polymer chains4
Total formula weight86015.01
Authors
Huo, J.,Zhou, D.,Ren, J.,Stuart, D.I. (deposition date: 2022-05-23, release date: 2022-06-29, Last modification date: 2024-01-31)
Primary citationTuekprakhon, A.,Nutalai, R.,Dijokaite-Guraliuc, A.,Zhou, D.,Ginn, H.M.,Selvaraj, M.,Liu, C.,Mentzer, A.J.,Supasa, P.,Duyvesteyn, H.M.E.,Das, R.,Skelly, D.,Ritter, T.G.,Amini, A.,Bibi, S.,Adele, S.,Johnson, S.A.,Constantinides, B.,Webster, H.,Temperton, N.,Klenerman, P.,Barnes, E.,Dunachie, S.J.,Crook, D.,Pollard, A.J.,Lambe, T.,Goulder, P.,Paterson, N.G.,Williams, M.A.,Hall, D.R.,Fry, E.E.,Huo, J.,Mongkolsapaya, J.,Ren, J.,Stuart, D.I.,Screaton, G.R.
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.
Cell, 185:2422-, 2022
Cited by
PubMed Abstract: The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread rapidly to become globally dominant and has split into a number of sublineages. BA.1 dominated the initial wave but has been replaced by BA.2 in many countries. Recent sequencing from South Africa's Gauteng region uncovered two new sublineages, BA.4 and BA.5, which are taking over locally, driving a new wave. BA.4 and BA.5 contain identical spike sequences, and although closely related to BA.2, they contain further mutations in the receptor-binding domain of their spikes. Here, we study the neutralization of BA.4/5 using a range of vaccine and naturally immune serum and panels of monoclonal antibodies. BA.4/5 shows reduced neutralization by the serum from individuals vaccinated with triple doses of AstraZeneca or Pfizer vaccine compared with BA.1 and BA.2. Furthermore, using the serum from BA.1 vaccine breakthrough infections, there are, likewise, significant reductions in the neutralization of BA.4/5, raising the possibility of repeat Omicron infections.
PubMed: 35772405
DOI: 10.1016/j.cell.2022.06.005
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.89 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon